Portfoliotracker

Formycon AG

FYB.DE · XETRA · Healthcare Biotechnology 27/100 E

15,40 €
▼ −0,02 (−0,13 %)
Trading delayed by 15 min
Price as of 17. 11. 13:19, fetched 17. 11. 13:39
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score27 / 100 Market cap275 mil. € P/E– Forward P/E13,9 P/S4,5 P/B0,7 EV/EBITDA12,7 Dividend yield– FCF yield-14,97 % EPS-1,42 € Net margin-41,0 % Return on equity-6,3 % Beta0,67 Debt / equity0,02
52-week range 13,60 to 26,95
3-month average volume0,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. Formycon AG has cooperation agreements with Biocelys S.A. and Santo Biosimilar GmbH in connection with a biosimilar candidate. It has a collaboration with Biocelys S.A. to develop the biosimilar candidate FYB286. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Employees
196
Country
Germany
Data since
4. 1. 2011

Explore further

Similar companies EVT.DETPE.DEEUZ.DEDMP.DEVBK.DE

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account